Main Objective of this study is to examine long-term safety of nivolumab in participants on treatment and in follow up.
Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
Cancer Nivolumab Nivolumab Dose 1 Nivolumab Dose 2
You can join if…
Open to people ages 18 years and up
Signed Written Informed Consent
Participants who have completed treatment with nivolumab, progressed on prior nivolumab treatment or discontinued nivolumab due to toxicity in the Parent Study are not eligible to receive nivolumab in this study. These participants may be enrolled for safety and survival follow-up only.
Participant is eligible for nivolumab treatment as per the Parent Study, and/or Investigator assessed clinical benefit, or
Participant is in or has completed the follow-up phase of the Parent Study i) Participant has completed or discontinued treatment, or ii) Participant has progressed on treatment, and/or iii) Participant is on subsequent therapy
You CAN'T join if...
Participant is not eligible for nivolumab treatment as per the Parent Study
Participants not receiving clinical benefit as assessed by the Investigator (participant is still eligible for study if entering survival follow-up only)
Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant
Participants in survival follow-up have no exclusion criteria.
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Melanoma Centeraccepting new patients San Francisco California 94143 United States
Local Institutionwithdrawn San Francisco California 94115 United States